welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Surgical Treatment of Familial Adenomatous Polyposis with an Open Technique. Experience of a Third Level Latin Ameri...INTRODUCTION : The ileal pouch-anal anas...
-
Papa’s Got A Brand New Bag!I miss you, I need you, and I’m scared...
-
Laparoscopic-Assisted Ileal Pouch-Rectal Muscle Sheath Anastomosis for the Treatment of Familial Adenomatous Polypos...PURPOSE: Familial adenomatous polyposis...
-
Bonnies Diary Oct 07https://jtvcancersupport.com/embed/26553...
-
Tucson drug startup launches gastric-cancer trialTucson-based drug startup Cancer...
-
French Digestive Polyposis CohorteFrench cohorte about polyposis digestive...
-
Body Image, Cosmesis, Quality of Life, and Functional Outcome of Hand-Assisted Laparoscopic Versus Open Restorative ...BACKGROUND : This study aimed to compare...